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Pediatric patients with SCID constitute
medical emergencies. In the absence of
an HLA-identical hematopoietic stem cell
(HSC) donor, mismatched related-donor
transplantation (MMRDT) or unrelated-
donor umbilical cord blood transplanta-
tion (UCBT) are valuable treatment op-
tions. To help transplantation centers
choose the best treatment option, we
retrospectively compared outcomes after
175 MMRDTs and 74 UCBTs in patients
with SCID or Omenn syndrome. Median
follow-up time was 83 months and
58 months for UCBT and MMRDT, respec-
tively. Most UCB recipients received a
myeloablative conditioning regimen; most
MMRDT recipients did not. UCB recipi-
ents presented a higher frequency of com-
plete donor chimerism (P  .04) and faster
total lymphocyte count recovery (P  .04)
without any statistically significance with
the preparative regimen they received.
The MMRDT and UCBT groups did not
differ in terms of T-cell engraftment, CD4
and CD3 cell recoveries, while Ig replace-
ment therapy was discontinued sooner
after UCBT (adjusted P  .02). There was
a trend toward a greater incidence of
grades II-IV acute GVHD (P  .06) and
more chronic GVHD (P  .03) after UCBT.
The estimated 5-year overall survival rates
were 62%  4% after MMRDT and
57%  6% after UCBT. For children with
SCID and no HLA-identical sibling donor,
both UCBT and MMRDT represent avail-
able HSC sources for transplantation with
quite similar outcomes. (Blood. 2012;
119(12):2949-2955)
Introduction
Primary immune deficiencies (PIDs) are a heterogeneous group of
genetic disorders of the immune system. They are characterized by
impairment of innate or adaptive immunity and, in some cases, other
concomitant disorders. SCIDs are among the most severe T-cell immune
deficiencies; sufferers are highly susceptible to infections and invariably
die within the first year of life if not treated.1 In 1968, hematopoietic
stem cell transplantation (HSCT) from an HLA-identical sibling donor
was shown to correct the immune function of a patient with SCID2
and has since become the treatment of choice, with overall survival
(OS) at 1 year having risen from 80% to 90%.3-5 Unfortunately,
because SCID is a genetic disease, less than 25% of these children
will have a healthy, HLA-matched sibling donor available.
The development of techniques for removing mature T cells
from BM grafts from mismatched related donors has made HSCT
applicable to virtually all patients.6 With better management of
supportive care and CD34 immunoselection, the OS of recipients
of mismatched related donor transplantations (MMRDTs) has
significantly improved and ranges from 54%-78% in more recent
studies.3-5 A study of the period between 2000 and 2005 found that
there was no significant difference in survival comparing a
well-HLA–matched unrelated adult stem cell with a mismatched
relative5; however, it is extremely important to bear in mind that the
time needed to find an appropriate, unrelated donor is a serious
limiting factor in this medical emergency setting.
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Umbilical cord blood transplantation (UCBT) was first reported
in 1989.7 Since that time, more than 20 000 UCBTs have been
performed worldwide (mainly for hematologic disorders).8 One
advantage of UCB as a stem cell source is the acceptable degree
of HLA mismatch, which increases the likelihood of finding a
suitable, unrelated donor. Given the urgency of these medical
situations, UCB constitutes a more readily available stem cell
source than an HLA-matched, unrelated HSCT donor. It has
been shown recently that UCBT in PID patients is a feasible
alternative.9-12
A critical end point after HSCT for PID is successful immune
reconstitution and the latter’s kinetics. In fact, after transplantation
of a T cell–depleted graft, circulating T cells may not be detected
for several months and normal counts are generally only achieved
between 6 and 12 months after transplantation. Slow T-cell
recovery is responsible for significant mortality and morbidity and
worsens the overall prognosis during the first year after transplanta-
tion.13,14 In UCBT, infused T cells are functionally naive and
posttransplantation immune reconstitution is slow compared with
recipients of nonmanipulated BM.15-17 However, to the best of our
knowledge, UCBT and MMRDT recipients have never been
formally compared in terms of the time course of immune
reconstitution.
In the absence of an HLA-identical sibling donor, the use of
immediately available sources of HSCs (such as MMRDs and
UCB) is subject to ongoing debate to determine the first-chance
therapy for SCID. Therefore, in the present study, we assessed and
compared the outcomes (ie, survival, occurrence of GVHD,
engraftment, and immune recovery) after MMRDT and UCBT in a
large cohort of children with SCID and Omenn syndrome in a
registry-based, retrospective study.
Methods
Patients
Data were collected from 2 European registries (Eurocord and Stem Cell
Transplant for Immunodeficiencies in Europ [SCETIDE]) operated for the
European Group for Blood and Marrow Transplantation (EBMT). Participa-
tion was open to European and non-European centers performing HSCT
with MMRDs or UCB for primary, severe T-cell immune deficiencies. Data
concerning patient and disease characteristics and transplantation outcomes
were collected with standardized questionnaires. Additional questionnaires
were sent out to collect missing or supplementary data.
Thirty-two centers supplied their data (between 1 and 50 cases per
center) for analysis. Each center was responsible for the quality control of
its own data. Data from Eurocord and SCETIDE were checked and
validated by a physician (J.F.F.) with experience with HSCT in PID
patients. The inclusion criteria for this retrospective analysis were as
follows: (1) children with severe T-cell deficiencies (SCIDs or Omenn
syndrome); (2) consecutive patients undergoing MMRDT or UCBT in
participating centers; and (3) transplantations performed between January
1995 and December 2005 inclusive. A total of 249 patients met these
inclusion criteria (MMRDT, n 175; UCBT, n  74). All participating
centers obtained informed consent from the parents to use blinded
information for scientific purpose in accordance with the Declaration of
Helsinki. The design and the objectives of the study were approved by the
scientific board of Eurocord, SCETIDE, and EBMT.
Definition of outcomes
Myeloid and T-cell engraftment. Engraftment was analyzed in patients
having survived for more than 28 days after transplantation and was defined
as an absolute neutrophil count above 0.5 109/L for 3 consecutive days
and/or donor chimerism. Lineage-specific chimerism data for the myeloid
(CD3) or T-cell (CD3) compartments were assessed for patients surviv-
ing 6 months after transplantation, and were available for a subset of
patients. For each cell lineage, mixed chimerism was defined as the
presence of 5%-95% of donor-derived cells. Engraftment failure was
defined by the absence of neutrophil recovery or the presence of at least
95% recipient chimerism (in both CD3 and CD3 compartments).
GVHD. Acute GVHD was diagnosed and graded according to the
Glucksberg criteria.18 Patients having survived for more than 100 days after
transplantation were evaluated for the presence of chronic GVHD, which
was diagnosed according to standard criteria.19
OS. OS time was defined as the time between transplantation and death
from any cause.
Immune recovery. Immune recovery was analyzed in the subgroup of
patients with donor chimerism who were alive at least 6 months after
transplantation. Total lymphocyte and absolute CD3 and CD4 cell counts
were assessed at 6, 12, and 24 months after transplantation. The time to
B-cell function recovery was estimated from the date of discontinuation of
intravenous Ig (IVIg) replacement therapy (ie, the time between transplan-
tation and the last day of IVIg infusion).
Statistical analysis
The MMRDT and UCBT groups were compared in terms of patient-,
disease-, and transplantation-related variables using a 2 test or Fisher exact
test for categorical variables and the Mann-Whitney test for continuous
variables. The primary end point was OS after transplantation according to
the Kaplan-Meier method. Cumulative incidence functions (CIFs) consider-
ing death and repeated transplantations as competing events were used to
estimate other end points, such as the incidence of GVHD and the
discontinuation of Ig replacement therapy. Univariate analyses were
performed using a log-rank test for OS and the Gray test for CIFs. Total
lymphocyte and absolute CD3 and CD4 cell counts measured 6, 12, and
24 months after transplantation were compared using the Mann-Whitney
test. Multivariate analyses were performed using a Cox proportional hazard
model for OS and a Fine-Gray model for CIFs.20 Factors with significantly
different distributions in the 2 groups or that were significantly associated
with OS were included in the multivariate model. All tests were 2-sided and
the threshold for statistical significance was set to P  .05. Statistical
analyses were performed with the SPSS Version 18 and S-Plus Version 8.1
(TIBCO) software packages.
Results
Patient, donor, and disease characteristics
Table 1 shows the characteristics of children with severe T-cell
deficiencies who received MMRDT (n 175) or UCBT (n 74).
A high proportion of the MMRDTs (88%) were performed in
4 European centers. In contrast, UCBTs were performed in
30 different centers, with 19 centers performing 1 or 2 transplanta-
tions and 4 centers performing more than 5 transplantations.
Only 4 centers performed both types of transplantations. In
comparison with MMRDT recipients, UCBT recipients had
undergone transplantation more recently (P  .03) and tended
to have a longer median time between diagnosis and transplanta-
tion (P  .06). The UCBT group had a higher proportion of
patients without T and B lymphocytes (TB) or Omenn
syndrome phenotype than the MMRDT group (P  .01). Before
transplantation, there were no intergroup differences in terms of
the frequency of failure to thrive, chronic diarrhea, respiratory
impairment, or the number of infections. However, pretransplanta-
tion viral infections were more common in the MMRDT group
(P  .02).
In the MMRDT group, the majority of patients (56%) received
BM as the stem cell source; most of the latter (68%) had 3 of
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6 HLA mismatches. All MMRD grafts were T-cell depleted
(mostly via CD34 cell selection). In the UCBT group, 50 (67%)
patients received grafts with 0 or 1 of 6 HLA mismatches and
24 (33%) received grafts with 2 or 3 HLA mismatches (considering
HLA-A and HLA-B in low-resolution typing and DRB1 in
high-resolution typing).
Transplantation characteristics
Preparative regimens varied according to the transplantation center,
the disease phenotype, and the patient’s health status before
transplantation (Table 1). Thirty transplantations in the MMRDT
group and 7 in the UCBT group were performed in the absence of
Table 1. Patient, disease, and transplantation characteristics for 249 children with severe T-cell deficiencies who received either UCBT
or MMRDT
UCBT (n  74) MMRDT (n  175) P
Median age at transplantation, mo (range) 6.4 (1-41) 6.5 (1-35) .87
Median time from diagnosis to transplantation, d (range) 55 (17-523) 46 (4-485) .06
Male sex, n (%) 42 (57%) 112 (64%) .28
Year of transplantation, n (%)
1995-2000 26 (35%) 87 (50%) .03
2001-2005 48 (65%) 88 (50%)
Diagnosis, n (%)
SCID TB* 36 (49%) 62 (36%) .01
Undefined TB 24 29
RAG1 or RAG2 deficiency 2 23
ADA deficiency 7 3
Reticular dysgenesis 3 7
SCID TB 23 (31%) 90 (51%)
Undefined TB 7 38
Gamma-chain deficiency 15 39
JAK3 deficiency 1 13
Omenn syndrome 15 (20%) 23 (13%)
Pretransplantation characteristics, events/available data, n (%)
Failure to thrive 39/69 (57%) 76/167 (46%) .12
Chronic diarrhea 28/66 (42%) 59/167 (35%) .31
Respiratory impairment 36/68 (53%) 84/166 (51%) .75
Infections
Viral 23/69 (33%) 83/164 (51%) .02
Bacterial 21/69 (30%) 59/128 (36%) .42
Fungal 12/69 (17%) 37/127 (23%) .38
Mycobacterial 8/69 (12%) 13/164 (8%) .37
P jiroveci 8/69 (12%) 28/164 (17%) .29
Transplantation characteristics, n (%)
Cell source
BM 99 (56%)
PBSCs 68 (39%)
BM  PBSCs 8 (5%)
UCB 74 (100%)
No. of HLA mismatches
0 21 (28%)
1 29 (39%) 15 (9%)
2 or 3 24 (33%) 160 (91%)
Conditioning regimen
No conditioning 7 (10%) 30 (17%) .04
Myeloablative (busulfan-based) 46 (62%) 81 (46%)
Reduced-intensity 20 (27%) 64 (37%)
ATG alone 5 6
Cy  other 2 10
Bu based ( 8 mg/Kg) 7 40
Other 6 8
Missing data 1 (1%)
Use of ATG or other mAbs 36 (49%) 47 (27%) .001
GVHD prophylaxis
None 1 (1.3%) 119 (68%)
CsA-based 71 (96%) 48 (27%)
Other 1 (1.3%) 2 (1%)
Missing data 1 (1.3%) 6 (4%)
Median follow-up, mo (range) 83 (5-162) 58 (3-157)
Myeloablative conditioning regimen in these patients consisted of Bu ( 8 mg/kg) and Cy (200 mg/kg total dose); no irradiation was used.
RAG indicates recombination activating gene; ADA, adenosine deaminase; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; ATG, anti-thymocyte globulin;
Bu, busulfan; Cy, cyclophosphamide; and CsA, cyclosporine A.
*This form of SCID is characterized by the complete absence of T and B lymphocytes (TB).
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conditioning. The majority of conditioning regimens contained
busulfan, which was combined with cyclophosphamide or fludara-
bine. Moreover, UCBT recipients were more likely to undergo
myeloablative conditioning than were MMRDT recipients
(P .04). Furthermore, the proportion of patients receiving antithy-
mocyte globulin or other mAbs was higher in the UCBT group than
in the MMRDT group (P  .001). The majority of MMRDT
recipients (n 119) did not receive any GVHD prophylaxis in
addition to T-cell depletion. Seventy-one (95%) of the UCBT
recipients received cyclosporine A (combined with steroids in 43 of
these patients).
Outcomes
Myeloid and T-cell engraftment. At 28 days after transplantation,
162 MMRDT recipients and 70 UCBT recipients were evaluable
for engraftment. Engraftment was observed in 126 patients (78%)
in the MMRDT group and 60 (86%) in the UCBT group (P  .14).
Lineage-specific chimerism data were available for a subset of
patients surviving 6 months after transplantation (MMRDT, n 77;
UCBT, n 36). When considering the (CD3) T-cell compart-
ment, 88% of MMRDT recipients and 97% of UCBT recipients had
full donor chimerism (P  .29). In the myeloid compartment
(CD3), full donor chimerism was achieved by more patients in the
UCBT group (75%) than in the MMRDT group (33%; P  .001).
This difference remained statistically significant when analyzing
patients receiving full myeloablative conditioning regimens and
those receiving reduced-intensity conditioning regimens separately
(data not shown). Two years after MMRDT, 2 patients presented
late graft failure (3 and 12 years after transplantation), but none
after UCBT.
Acute and chronic GVHD. There was a trend toward a higher
cumulative incidence of grades II-IV acute GVHD in UCBT
recipients relative to MMRDT recipients (34%  6% and
22% 3%, respectively; P  .06). Furthermore, the cumulative
incidence of chronic GVHD was significantly higher in the
UCBT group than in the MMRDT group (22%  5% and
10%  2%, respectively; P  .03). Nineteen patients in the
MMRDT group had chronic GVHD (limited, n  11; extensive,
n  8) compared with 17 patients in the UCBT group (limited,
n  9; extensive, n  8).
Immune recovery. Table 2 shows the number of patients with
data on lymphocyte, CD3, and CD4 cell counts at 6, 12, and
24 months after transplantation. The UCBT recipients had greater
total lymphocyte recovery than the MMRD recipients (P  .043).
However, there were no statistically significant differences be-
tween the 2 groups in terms of T-cell lymphocyte (CD3 and
CD4) recoveries at any time point. Compared with MMRDT
recipients, the UCBT recipients had a higher cumulative incidence
of discontinuation of IVIg replacement therapy. At 3 years,
45% 6% of the UCBT recipients had discontinued Ig replace-
ment therapy, compared with 31% 4% of the MMRDT recipi-
ents (P  .023; Figure 1A). This observation was confirmed in a
multivariate analysis after adjustment for intergroup differences
(Table 3). Other factors associated with better B-cell function
recovery were the absence of pretransplantation infections and use
of a myeloablative conditioning regimen (not shown).
OS. In a nonadjusted, univariate analysis, the estimated 5-year
OS was 62% 4% for MMRDT recipients and 57% 6% for
UCBT recipients (P  .68; Figure 1B). In the MMRDT group,
46 (28%) patients underwent a second transplantation for non-
engraftment compared with 7 (9.5%) in the UCBT group (P .002);
of these, 59% and 47% survived, respectively. In a multivariate
Figure 1. Kinetics of Ig therapy discontinuation and overall survival in the
2 study groups. (A) Three-year cumulative incidence of discontinuation of IVIg
replacement therapy in the MMRDT and UCBT groups. (B) Probability of 5-year OS
for SCID patients according to the use of MMRDT or UCBT.
Table 2. Total absolute counts for lymphocytes, CD3, and CD4
cells as a function of the transplantation approach (UCBT vs
MMRDT)
UCBT MMRDT P
Total lymphocyte count
6 mo n 40 84 .001
Mean 3448 2227
12 mo n 36 82 .008
Mean 5207 3690
24 mo n 32 75 .18
Mean 3914 3657
CD3 T-cell count
6 mo n 37 85 .19
Mean 1447 1269
12 mo n 33 82 .13
Mean 2892 2435
24 mo n 28 74 .67
Mean 2582 2545
CD4 T-cell count
6 mo n 38 86 .98
Mean 557 590
12 mo n 33 83 .49
Mean 1380 1145
24 mo n 29 75 .89
Mean 1221 1212
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analysis adjusted for differences between the 2 groups (ie, year of
transplantation, diagnosis, presence of pretransplantation infec-
tions, and the use of myeloablative conditioning), there was no
significant difference in OS between the 2 groups (P  .58; Table
3). Other prognostic factors associated with decreased survival are
given in Table 3. A total of 97 patients died: 67 in the MMRDT
group and 30 in the UCBT group. The causes of death are shown in
Table 4. It is noteworthy that infections represented the most
frequent cause of death in both groups.
Discussion
The objective of the present study was to compare the outcomes of
transplantation with 2 different stem cell sources retrospectively to
help transplantation centers choose the best treatment option. There
were notable differences in the number of transplantations per-
formed by each transplantation center. The fact that few centers
performed MMRDT is almost certainly explained by the need for
specific ex vivo graft processing technology to eliminate mature
donor T cells.4 In contrast, many transplantation centers were able
to perform UCBT because of the absence of graft manipulation in
this latter technique. A center effect on outcomes has been reported
for MMRDT21 and UCBT (Eurocord unpublished data) procedures
in children with acute lymphoblastic leukemia. Unfortunately, only
4 centers in our study performed both techniques, and this
prevented us from testing for a center effect that could have
introduced bias into this retrospective study. Nevertheless, we
showed that the UCBT and MMRDT groups did not differ
significantly in terms of 5-year survival despite a higher incidence
of chronic GVHD in UCBT recipients.
The 2 groups were found to differ significantly in terms of
several patient-, disease-, and transplantation-related factors. It is
well known that a B-negative SCID phenotype influences the
outcome whether assessed as survival or immune reconstitu-
tion.4,5,14,22,23 In the present study, more UCBT recipients with
B-negative SCID phenotype were enrolled. However, in a multivar-
iate analysis, only patients with Omenn syndrome had a relatively
low survival rate. Conversely, SCID patients who underwent
MMRDT were more likely to have suffered from a viral infection
before transplantation, a setting known to be associated with an
adverse prognosis.4,5
Another donor-related factor was the significantly different
number of HLA mismatches in the 2 groups. The majority of
MMRDT patients had 3 of 6 HLA mismatches, whereas UCBT
patients received grafts with 0 HLA mismatches (ie, 6 matches;
n  21) or 1 of 6 HLA mismatches (ie, 5 matches; n 29). It is
interesting to speculate on how to build an algorithm for UCBT
versus MMRDT donor choice. It is well known that the outcome
for UCBT patients with nonmalignant diseases is correlated with
the cell dose (the number of cells infused per kilogram of
bodyweight)24 and the degree of HLA mismatch. Cell dose is not an
issue in this particular pediatric population. The OS was higher in
UCBT patients with 6 of 6 matches (76% 9%, n 21) or 5 of
6 matches (62% 10%, n 29) than in those with 4 of 6 HLA
matches (35% 10%, n 24; supplemental Figure 1, available on
the Blood Web site; see the Supplemental Materials link at the top
of the online article). In fact, because only 24 UCBT recipients
were given a HLA 4 of 6 or 3 of 6 CB graft, we were not able to
compare this group with the MMRDT group because of the
impossibility of adjusting for the risk factors. Therefore, any
definitive conclusion based on this small population should be
taken with caution because we do not know if the worse outcomes
observed were independently associated with a 4 or 3 of 6 CB graft
or other, patient-, disease-, or transplantation-related factors. How-
ever, based on a larger series of patients with nonmalignant
diseases (including aplastic anemia, metabolic diseases, and other
genetic diseases), Eurocord has recommended avoiding grafts with
2 or more HLA mismatches because of worse outcomes.25
The MMRDT and UCBT groups had similar engraftment rates.
However, a higher proportion of patients in the MMRD group had
to undergo a repeated transplantation as a result of poor graft
function compared with UCB recipients. This finding could be
related to the higher frequency of complete donor chimerism in
myeloid cells in UCBT recipients, as reported previously.5,26
However, the higher proportion of myeloid donor chimerism may
also be related to the fact that most UCBT recipients underwent
myeloablative conditioning. In a multivariate analysis, we found
that use of a myeloablative preparative regimen was associated
with better OS. In both groups of patients, the major cause of death
was infection; this emphasizes the importance of the time course of
immune reconstitution. Despite the observation that UCB recipi-
ents had higher total lymphocyte counts during the first year after
Table 4. Causes of death in MMRDT and UCBT recipients
Cause of death UCBT (n  30) MMRDT (n  67)
Infection 9 31
GVHD 6 6
ARDS 6 15
Rejection 2 5
SOS 2
Cardiac toxicity 2
MOF 2 1
Secondary malignancy 1 2
Other 2 5
ARDS indicates acute respiratory distress syndrome; SOS, hepatic sinusoidal
obstruction syndrome; and MOF, multiorgan failure.
Table 3. Multivariate analyses of transplantation outcomes for
severe T-cell deficiency patients according to strategy of
transplantation (MMRDT vs UCBT)
HR 95% CI P
5-year OS
MMRDT vs UCBT 1.15 0.71-1.87 .58
Year 2001 1.08 0.71-1.65 .72
Omenn vs SCID 1.99 1.16-3.39 .01
Failure to thrive 0.55 0.33-0.91 .02
Diarrhea 3.34 1.20-3.34 .007
Pretransplantation viral infection 2.32 1.47-3.67 .000
RIC vs no conditioning 0.24 0.12-0.47 .000
Myeloablative conditioning vs no conditioning 0.36 0.20-0.66 .001
Use of ATG or other mAb 1.73 1.05-2.85 .032
Discontinuation of IVIg replacement therapy
MMRDT vs UCBT 1.70 1.08-2.69 .023
Year 2001 1.52 0.97-2.39 .07
Omenn vs SCID 0.68 0.34-1.32 .25
Failure to thrive 0.76 0.48-1.23 .27
Diarrhea 1.57 0.94-2.61 .08
Pretransplantation viral infection 1.82 1.12-2.95 .015
RIC vs no conditioning 2.13 0.92-4.96 .08
Myeloablative conditioning vs no conditioning 3.23 1.47-7.08 .003
Use of ATG or other mAb 0.64 0.39-1.04 .07
HR indicates hazard ratio; RIC, reduced-intensity conditioning; and ATG, antithy-
mocyte globulin.
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transplantation, CD3 and CD4 T-cell numbers did not signifi-
cantly differ at any time point. Therefore, the higher total lympho-
cyte counts recorded soon after transplantation in UCB recipients
probably correspond to B and/or natural killer cells, as has already
been reported by the Eurocord group and others.11,15,17 Accordingly,
the UCBT recipients studied here were able to discontinue IVIg
replacement therapy sooner and more frequently compared with
MMRDT recipients. However, this parameter did not appear to
influence the total number of deaths from infections in the 2 groups.
It would be interesting to look at long-term outcomes, because
this analysis gather patients with long term follow up. However,
because of the retrospective and multicenter nature of our study,
these outcomes were not defined previously and might reflect only
a tendency for long-term follow-up of these patients. In addition,
we were able to collect information on only a subset of this group
of patients. Neurologic development, growth, and school atten-
dance were normal in 88%, 55%, and 89% of patients surviving
more than 2 years in the MMRDT group and in 90%, 66%, and
74% in the UCBT group, respectively. Secondary malignancies
were observed in 3 patients after MMRDT, one with a posttransplan-
tation lymphoproliferative disease and 2 with myelodysplastic
syndrome (MDS). These 2 patients with MDS were SCID patients
with reticular dysgenesis, and the development of MDS was
associated with a genetic defect rather than with a transplantation
modality.27 None of the patients developed secondary malignancies
after UCBT.
In conclusion, MMRDT and UCBT are both valid options in
SCID patients lacking an HLA-identical sibling donor. Therefore,
each transplantation center should choose the strategy as a function
of their own experience and skills, while considering the rapid
availability of suitable UCB or the availability of techniques for the
efficient removal of mature T cells from MMRD grafts. Strategies
capable of speeding up immune reconstitution in these severely
affected patients could produce significant improvements in out-
come for both transplantation approaches.
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